Clinical Trials Logo

Clinical Trial Summary

This study will compare the efficacy and cost effectiveness of two methods of treating adolescents with attention deficit hyperactivity disorder in school.


Clinical Trial Description

Attention deficit hyperactivity disorder (ADHD) is characterized by inattention, hyperactivity, and impulsivity. Approximately 50% to 70% of children who had ADHD continue to meet its criteria in adolescence, but the problems stemming from adolescent ADHD can be more serious—including an increased risk of substance use, delinquency, academic failure, serious social impairment, and legal problems. Problems in school more than double when students with ADHD move from elementary school to middle and high school.

Treating ADHD with medications alone is often ineffective, but adding other methods, such as behavioral treatments, may be beneficial. Researchers have developed a psychosocial treatment for adolescents with ADHD, called the Challenging Horizons Program (CHP), that is delivered in school and targets social impairment, family conflict, and academic failure. Two versions of CHP were developed, an after-school model and a consultation model. The after-school model involves 2 to 3 days of individualized treatment per week and has a higher cost than the consultation model because it involves hiring specialized counseling staff and finding space to house the program after school. The consultation model involves teaching CHP intervention strategies to school staff, who then mentor students with ADHD and deliver interventions as needed to solve problems. This model is less expensive, but it does not deliver treatment as often or consistently as the after-school model. This study will compare the after-school and consultation models of the CHP to determine their relative efficacy and cost effectiveness. The study will also evaluate factors that may predict which adolescents would benefit most from either of the two models.

Participation in this study will last a full school year. Participants from schools taking part will be randomly assigned to one of three groups: after-school CHP, consultation CHP, or standard community care. Participants receiving after-school CHP will attend two 2.5-hour after-school sessions per week in which they will work with counselors on homework management, educational skills, and interpersonal skills. Participants receiving consultation CHP will be assigned a teacher mentor (who will volunteer to work with the student), and the mentor and student will meet as needed. A study clinician will provide support to the teacher mentors, who will learn the same interventions as counselors in the after-school condition. Participants in the community care condition will not receive any intervention but will receive a list of community psychosocial and medical service providers for children and their families. All participants will undergo study assessments pre-treatment; in November, January, and March of the school year; post-treatment; and at a 6-month follow-up. Assessments will include questionnaires and clinical interviews completed by student, their parents, and their teachers. ADHD symptoms, academic performance, relevant skills of adolescents, and program costs will be assessed. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Attention Deficit Disorder With Hyperactivity
  • Hyperkinesis

NCT number NCT00947973
Study type Interventional
Source Children's Hospital Medical Center, Cincinnati
Contact
Status Completed
Phase Phase 2
Start date July 2010
Completion date July 2014

See also
  Status Clinical Trial Phase
Completed NCT00202605 - Safety and Efficacy of SPD465 in Adults With ADHD Phase 2
Not yet recruiting NCT02677519 - A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD Phase 4
Completed NCT02730572 - Concerta (Methylphenidate) -To-Generic Switch Study N/A
Completed NCT01681082 - Psychological Effects of Tai Chi Training N/A
Active, not recruiting NCT01330693 - Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy Phase 3
Completed NCT00830700 - Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study N/A
Completed NCT01012622 - An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD) Phase 4
Completed NCT00626236 - Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems Phase 2
Completed NCT00598182 - Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study N/A
Completed NCT00381407 - Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder N/A
Completed NCT00178503 - Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children Phase 2/Phase 3
Completed NCT00247572 - Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Phase 2
Completed NCT00118911 - Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder N/A
Completed NCT00218322 - Effectiveness of ATMX in Treating Adolescents With ADHD and SUD Phase 4
Completed NCT00557011 - NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD Phase 2
Completed NCT00071656 - Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I N/A
Active, not recruiting NCT00057668 - Preventing Behavior Problems in Children With ADHD Phase 2
Completed NCT00050622 - Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT00050050 - Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder Phase 1
Completed NCT00031395 - Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children Phase 3